Scynexis Inc Total Liabilities
Scynexis Inc total liabilities. Based on the latest financial reports, Scynexis Inc (SCYX) has total liabilities worth $8.04 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Scynexis Inc (SCYX) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Scynexis Inc (2012–2025)
Total liabilities of Scynexis Inc from 2012 to 2025. This chart illustrates how Scynexis Inc's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Scynexis Inc to see how much of total assets are deployed in long-term investments.
Scynexis Inc Competitors by Total Liabilities
The table below lists competitors of Scynexis Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
N2N Connect Bhd
KLSE:0108
|
Malaysia | RM26.89 Million |
|
Nyxoah
BR:NYXH
|
Belgium | €42.65 Million |
|
BII Railway Transportation Technology Holdings Company Limited
F:CN6
|
Germany | €1.97 Billion |
|
Namhwa Industrial Co. Ltd
KQ:111710
|
Korea | ₩14.98 Billion |
|
Sun Peak Metals Corp
V:PEAK
|
Canada | CA$392.70K |
|
Lokotech Group AS
OL:LOKO
|
Norway | Nkr26.26 Million |
|
CMR S.A.B. de C.V
MX:CMRB
|
Mexico | MX$3.23 Billion |
|
Petrolia SE
OL:PSE
|
Norway | Nkr30.52 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Scynexis Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Scynexis Inc asset portfolio.
Liquidity & Leverage Metrics
Scynexis Inc Total Liabilities Ratios Explained
Scynexis Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Scynexis Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Scynexis Inc (2012–2025)
The table below shows the annual total liabilities of Scynexis Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $9.65 Million | -72.86% |
| 2024-12-31 | $35.57 Million | -35.86% |
| 2023-12-31 | $55.45 Million | -34.44% |
| 2022-12-31 | $84.58 Million | +7.63% |
| 2021-12-31 | $78.58 Million | -1.50% |
| 2020-12-31 | $79.78 Million | +80.26% |
| 2019-12-31 | $44.26 Million | +101.68% |
| 2018-12-31 | $21.95 Million | -10.21% |
| 2017-12-31 | $24.44 Million | -2.13% |
| 2016-12-31 | $24.97 Million | +240.97% |
| 2015-12-31 | $7.32 Million | +17.35% |
| 2014-12-31 | $6.24 Million | -70.48% |
| 2013-12-31 | $21.14 Million | -32.78% |
| 2012-12-31 | $31.45 Million | -- |
About Scynexis Inc
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the tre… Read more